Wisevoter
Baltimore

SereNeuro Therapeutics Secured Pre-Seed Funding

The Baltimore-based startup raised capital to advance its non-opioid osteoarthritis therapy.

Updated on Oct. 5, 2026 in Arthritis

A precision laboratory glass pipette lying on a brushed metal surface next to a glass slide with a single fluid drop.
SereNeuro Therapeutics, a Johns Hopkins University spinout based in Baltimore, has closed a pre-seed funding round to advance its non-opioid osteoarthritis treatment. AI Illustration. Upload story photo >

Live Poll

Should medical development prioritize non-opioid pain management therapies over existing treatments?

Johns Hopkins University spinout SereNeuro Therapeutics has officially closed a pre-seed funding round. The company is developing a non-opioid therapy designed to treat osteoarthritis joint pain.

Why it matters

The company aims to address chronic joint pain by utilizing a unique therapy candidate that targets pain-sensing neurons. This approach provides a potential alternative to traditional opioid treatments for patients suffering from osteoarthritis.

SereNeuro Therapeutics secured a $318,000 Small Business Innovation Research grant from the National Institutes of Health. Total capital raised by the startup reached $898,765 as of early 2026.

The players

SereNeuro Therapeutics

This Baltimore-based biotech firm is a Johns Hopkins University spinout focused on developing non-opioid therapies for joint pain.

Laura Richman

She serves as the part-time chief science officer for SereNeuro Therapeutics.

National Institutes of Health

This federal agency provided the Small Business Innovation Research grant to support the development of the startup's pain therapy.

The details

Founded in 2024, the Baltimore-based firm utilizes a therapy candidate known as SN101 that injects pain-sensing neurons into joints to act as a sponge for inflammatory signals. The company has already conducted tests in primates and analyzed human joint fluid samples.

Timeline

  1. 2024: SereNeuro Therapeutics was founded.

  2. Early 2026: The company reached $898,765 in total capital raised.

  3. October 5, 2026: SereNeuro announced the close of its pre-seed funding.

  4. November 2026: SereNeuro plans to meet with the FDA.

Health Landscape

The startup's progress follows the trajectory set by the Small Business Innovation Research program, which supports high-risk early-stage technology development. This funding helps bridge the gap between academic innovation and the clinical testing required for medical breakthroughs.

If successful, this non-opioid therapy could offer Baltimore residents and other patients a new method to manage chronic joint discomfort without the risks associated with opioids. Patients should monitor clinical trial updates as the company initiates formal FDA development processes.

The takeaway

Advancements in non-opioid pain management represent a significant shift in how chronic conditions like osteoarthritis are treated. Patients and providers should watch for future clinical trial data as the development of targeted neurological therapies continues to evolve.

What happens next

SereNeuro Therapeutics has scheduled a formal meeting with the FDA in November 2026 to discuss and initiate the development process for its therapy candidate.

Further reading

For more information on ongoing research and developments in this field, visit our Arthritis section.

Live Poll

Should medical development prioritize non-opioid pain management therapies over existing treatments?